Certuity LLC Acquires 776 Shares of Sanofi (NASDAQ:SNY)

Certuity LLC grew its holdings in Sanofi (NASDAQ:SNY) by 20.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,592 shares of the company’s stock after purchasing an additional 776 shares during the quarter. Certuity LLC’s holdings in Sanofi were worth $221,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Franklin Resources Inc. raised its stake in Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after buying an additional 395,744 shares in the last quarter. Natixis Advisors LLC increased its holdings in shares of Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after acquiring an additional 114,133 shares during the period. Raymond James & Associates raised its position in shares of Sanofi by 4.8% in the 3rd quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock worth $162,479,000 after acquiring an additional 129,472 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Finally, DAVENPORT & Co LLC boosted its position in Sanofi by 40.7% during the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of recent research reports. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Trading Down 1.0 %

Shares of NASDAQ:SNY opened at $53.99 on Friday. The business’s 50-day moving average is $50.18 and its 200 day moving average is $52.42. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The firm has a market capitalization of $137.02 billion, a P/E ratio of 21.68, a P/E/G ratio of 0.99 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. On average, research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.